Skip to content

Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients

Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02851550
Acronym
LALTH-2
Enrollment
100
Registered
2016-08-01
Start date
2015-12-31
Completion date
2018-06-30
Last updated
2016-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Post-transplant Patients

Keywords

liver, transplant, Lysosomal Acid Lipase

Brief summary

Lysosomal Acid Lipase (LAL) deficiency is a rare, autosomal recessive storage disease linked to decrease enzymatic activity of LAL, responsible for intracellular accumulation of cholesterol esters and triglycerides. The accumulation of lipid is in hepatocytes, Kupffer cells and macrophages leading to a fatty liver, hepatic fibrosis that can evolve up to cirrhosis. LAL deficiency is responsible for significant morbidity and early mortality in children, adolescents and adults in connection with a multi visceral disease reaching the liver, gastrointestinal tract and the vascular endothelium. The disease is caused by homozygous or heterozygous mutations in the gene (LIPA chromosome 10q23.2-23.3) which is responsible for the synthesis of the LAL. The disease can be diagnosed by enzymatic analysis using few drops of blood absorbed onto blotting paper. Patients with this deficiency LAL, have no or reduced activity of this enzyme. Because of its rarity, the deficit in LAL is under diagnosed or is diagnosed in patients with liver biological disturbances and / or lipid profile disturbances, steatohepatitis-hepatitis (NASH), the steatosis (NAFLD), the cryptogenic cirrhosis or Wilson disease. Inclusion period of 12 to 18 months (100 patients).

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* liver post-transplant patient * patients with cryptogenic cirrhosis, NASH

Exclusion criteria

* Patients without metabolic syndrome clinical, biological or radiological.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of Lysosomal Acid Lipase deficiency in liver post-transplant patientsDuring the routine visit (Day 1)Assessment of the prevalence of Lysosomal Acid Lipase deficiency in liver post-transplant patients

Countries

France

Contacts

Primary ContactSylvie Radenne, MD
sylvie.radenne@chu-lyon.fr(0)4 26 10 93 59
Backup ContactIsabelle Delfour
isabelle.delfour@chu-lyon.fr(0)4 26 73 27 25

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026